Mouse SCNT ESCs Have Lower Somatic Mutation Load Than Syngeneic iPSCs  by Li, Zhe et al.
Stem Cell Reports
ReportMouse SCNT ESCs Have Lower Somatic Mutation Load Than
Syngeneic iPSCs
Zhe Li,1,3,4 Hongxia Lu,2,4 Weifeng Yang,2 Jun Yong,2 Zhen-ning Zhang,1 Kun Zhang,3,* Hongkui Deng,2,*
and Yang Xu1,*
1Division of Biological Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0322, USA
2College of Life Sciences, Peking University, Beijing 100871, China
3Department of Bioengineering, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0322, USA
4These authors contributed equally to this work
*Correspondence: kzhang@bioeng.ucsd.edu (K.Z.), hongkui_deng@pku.edu.cn (H.D.), yangxu@ucsd.edu (Y.X.)
http://dx.doi.org/10.1016/j.stemcr.2014.02.005
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYEctopic expression of reprogramming factors has been widely adopted to reprogram somatic nucleus into a pluripotent state (induced
pluripotent stem cells [iPSCs]). However, genetic aberrations such as somatic gene mutation in the resulting iPSCs have raised concerns
regarding their clinical utility. To test whether the increased somatic mutations are primarily the by-products of current reprogramming
methods, we reprogrammed embryonic fibroblasts of inbred C57BL/6 mice into either iPSCs (8 lines, 4 previously published) or embry-
onic stem cells (ESCs) with somatic cell nuclear transfer (SCNT ESCs; 11 lines). Exome sequencing of these lines indicates a significantly
lower mutation load in SCNT ESCs than iPSCs of syngeneic background. In addition, one SCNT-ESC line has no detectable exome
mutation, and two pairs of SCNT-ESC lines only have shared preexistingmutations. In contrast, every iPSC line carries uniquemutations.
Our study highlights the need for improving reprogramming methods in more physiologically relevant conditions.INTRODUCTION
Reprogramming of somatic nuclei into a pluripotent state
can be achieved through either somatic cell nuclear trans-
fer (SCNT) (Campbell et al., 1996) or ectopic expression
of reprogramming factors in somatic cells to generate
induced pluripotent stem cells (iPSCs) (Takahashi et al.,
2007; Yu et al., 2007). The latter approach has become
widely adopted because it is ethically more acceptable
and technically more feasible to many organisms such as
humans. The iPSCs are functionally indistinguishable
from embryonic stem cells (ESCs). However, recent studies
have revealed genetic and epigenetic aberrations in the
resulting iPSCs (Gore et al., 2011; Cheng et al., 2012; Ji
et al., 2012; Lister et al., 2011; Ruiz et al., 2012, 2013; Young
et al., 2012). For example, it has been shown that iPSCs
always possess somatic-coding mutations (Gore et al.,
2011; Ji et al., 2012; Ruiz et al., 2013; Young et al., 2012),
leading to the concern for the safety of such cells in clinical
application.
SCNT has been widely used to reprogram the somatic
nucleus into a pluripotent state by the injection of a donor
nucleus into an enucleated oocyte. The technique mimics
the process of early embryonic development except that
the blastocyst formed contains identical genomic DNA as
the donor (Figure 1). Because SCNT provides a physiologi-
cally relevant condition for nuclear reprogramming and
allows development, it has beenwidely adopted to produce
viable cloned mammals such as sheep (Campbell et al.,
1996), mice (Wakayama et al., 1998), and rabbit (Chesne´Stemet al., 2002) from primary culture. There is also an ongoing
effort to derive human ESC-like lines using SCNT (SCNT
ESCs) for patient-specific therapy (Egli et al., 2011; Tachi-
bana et al., 2013). However, the genetic integrity of these
SCNT ESCs has yet been reported.
In this study, we characterized the protein-coding region
of 8 iPSC lines and 11 SCNT-ESC lines derived from a
syngeneic inbred mouse background at single-nucleotide
resolution. We chose to focus on exome not only due to
cost considerations but also because exome mutations are
more interpretable, and the iPSC mutation load in exome
has been well characterized (Gore et al., 2011; Ji et al.,
2012; Ruiz et al., 2013; Young et al., 2012). We observed
significantly lower somatic-coding mutation load in
SCNT ESCs than iPSCs. These findings suggest that current
reprogramming methods to generate iPSCs could be
improved in more physiologically relevant conditions to
optimize nuclear reprogramming for clinical application.RESULTS
Previous studies have reported that human iPSCs derived
from diverse somatic origins and reprogramming methods
all carried between 2 and 14 point mutations in protein-
coding regions (Gore et al., 2011; Ji et al., 2012; Ruiz
et al., 2013). In this study, we sought to determine
whether acquisition of protein-coding mutations must
occur to allow successful nuclear reprogramming. To
avoid the influence of distinct genetic backgrounds onCell Reports j Vol. 2 j 399–405 j April 8, 2014 j ª2014 The Authors 399
Figure 1. Summary of Pairwise Com-
parison between Mouse Fibroblast and
Pluripotent Stem Cell Lines
The bold numbers in parentheses indicate
validated/unique somatic-coding muta-
tions. Footnote 1 is previously described in
Zhao et al., 2011. Footnote 2 is previously
described in Araki et al., 2013. E13.5,
embryonic day 13.5.
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4 mouse iPSC lines from the syngeneic mouse embryonic
fibroblasts (MEFs) of the inbred C57BL/6 (B6) mice (Fig-
ure 1). The B6 iPSCs were reprogrammed with the integra-
tion-free approaches by Abe’s and our group (Araki et al.,
2013; Zhao et al., 2011), and the SCNT ESCswere generated
as we previously described (Bai et al., 2007; Jiang et al.,
2008; Yu et al., 2005). The pluripotency of these cell lines
was extensively characterized by the surface expression of
ESC-specific markers, their capability to differentiate into
each of the three germ layers, or in most cases, by their
capability to contribute to adult chimeric mice and germ-
line transmission (Figures 2A–2D; Figures S1 and S2 avail-
able online). We next performed exome sequencing and
pairwise comparison of the 19 pluripotent stem cell lines
and progenitor MEF cells (Figure 1). After mapping
sequenced reads, 90% or more of protein-coding regions
had sufficiently high sequence coverage (>103) and
consensus quality (>30) to identify somatic-coding muta-
tions in each cell line (Table 1). We identified and validated
a total of 78 unique somatic-coding mutations within 8
iPSC lines (Tables 1, 2, and S1), or an average of 9.8 muta-
tions per line, consistent with previously observed muta-
tional load in human iPSC lines (Gore et al., 2011). In
contrast, 31 unique mutations were identified and vali-
dated in the 11 SCNT-ESC lines, leading to a projection of
2.8 mutations per line in protein-coding regions (Tables
1, 2, and S1). The mutational load of iPSC lines was signif-
icantly higher than that of SCNT-ESC lines (p < 0.004,
Mann-Whitney U test).
In contrast to the findings that every iPSC line examined
in this and previous studies harbored protein-codingmuta-400 Stem Cell Reports j Vol. 2 j 399–405 j April 8, 2014 j ª2014 The Authortions, we did not detect any protein-coding mutation in
one SCNT-ESC line (Table 1, SCNT2). Moreover, there
were two pairs of SCNT-ESC lines (SCNT3 and SCNT4 and
SCNT6 and SCNT10) that only had shared somatic muta-
tions (Table 2), suggesting that these mutations were not
introduced during reprogramming but, instead, were pre-
sent in the fibroblast progenitors. In SCNT-ESC lines, the
blastocyst formed contains identical genomic information
as the donor (Figure 1). Given the nature of this technique,
any sharedmutations in SCNT ESCs derived from the same
donor cells were possibly inherited from a rare parental
fibroblast carrying these mutations. None of these muta-
tions located in any of the known mutation hot spots, so
the possibility of seeing two mutations occurring at the
same position due to ‘‘mutation hot spots’’ was too low
even for one line. After removing these potentially preex-
isting shared mutations, four SCNT-ESC lines carried no
detectable codingmutations introduced during reprogram-
ming. In contrast, all mutations identified in the iPSC lines
were unique. We observed great variability in somatic-
coding mutational load across SCNT-ESC and iPSC lines
that contributed to chimeric mice. Therefore, these detect-
able mutations appear to have no apparent functional
consequence in development. Furthermore, none of the
mutated genes clusters in a specific functional pathway.DISCUSSION
The major advantage of using cells from an inbred mouse
strain for the comparison of various reprogramming tech-
nologies was that the MEFs isolated from these mice weres
Figure 2. Summary of Mouse SCNT-ESC and iPSC Line Characterization
(A) Establishment of SCNT-ESC lines from MEFs.
(B) Pluripotency of SCNT ESCs in vivo. Left panel shows chimeric mice derived from SCNT-ESC lines. SCNT1 cells were injected into eight-cell
embryos of ICR mice, and shown are 8-week-old offspring, in which black coat color is derived from the SCNT-ESC contribution. Right panel
shows the male that was crossed with a white ICR female, producing a litter containing nine black offspring, confirming the contribution of
SCNT1 to the germline. Asterisks in the left and right panels indicate the same male.
(C) Summary of mouse SCNT-ESC line characterization. The percentage of chimerism was established based on coat color. ND, not
determined.
(D) Summary of mouse iPSC line characterization.
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that have much more genetic variability. It also enables
more comprehensive pluripotent functionality testing
such as the contribution to chimeric mice. In addition,
genetic difference between inbred mice is usually present
as homozygous variants, whereas somatic mutations
would always appear as heterozygous. By exome sequenc-
ing of SCNT ESCs and iPSCs reprogrammed from syngeneic
mouse B6 fibroblasts, we were able to perform a direct
comparison of the somatic mutation load between the
two nuclear-reprogramming methods.
Previous studies reported an average of 6–12 somatic-
coding mutations in human iPSC lines when compared
against their corresponding somatic cell of origin (Gore
et al., 2011; Ji et al., 2012; Ruiz et al., 2013). We discovered
that, at least in mouse cells, the somatic mutation load in
SCNT-ESC lines was significantly lower than that of iPSC
lines. Furthermore, one of the SCNT-ESC lines has no
detectable coding mutation. Studies have suggested that
some but not all identified somatic variants in iPSCs,Stemsuch as point mutations and copy number variations,
were present in their progenitor cells, whereas others
were introduced during reprogramming (Abyzov et al.,
2012; Gore et al., 2011; Young et al., 2012). Therefore,
our findings of two pairs of SCNT-ESC lines that only
harbor shared mutations suggest that genetic variants
most likely preexisted in the somatic population of origin,
without acquiring any additional coding somaticmutation
during reprogramming. The differential somatic mutation
load in pluripotent stem cells reprogrammed with the
twomethods could be due to the difference in their deriva-
tion time. In this context, the iPSCs are established 2–
4 weeks after ectopic expression of transcription factors,
whereas SCNT ESCs are established 4 days after oocyte acti-
vation. Therefore, it is very likely that formation of iPSCs
has to go through additional rounds of cell division and a
potentially more stressful condition when compared to
SCNT ESCs. Taking into consideration the differential
reprogramming time, the iPSCs spent an average of 50–
77 days in culture, whereas SCNT ESCs spent an averageCell Reports j Vol. 2 j 399–405 j April 8, 2014 j ª2014 The Authors 401
















SCNT1 13,147,531,800 95% 88% 30 31,194,049 9/9 9
SCNT2 10,427,221,300 94% 85% 29 31,222,097 0/0 0
SCNT3 4,996,365,000 90% 75% 33 30,799,305 3/3 0
SCNT4 4,744,153,500 90% 74% 33 30,790,251 3/3 0
SCNT5 6,213,421,800 92% 80% 33 31,200,714 2/2 2
SCNT6 5,168,988,000 89% 74% 33 31,155,933 5/5 0
SCNT7 5,686,592,400 90% 76% 33 31,171,629 1/5 1
SCNT8 5,525,811,400 90% 77% 32 31,159,710 6/6 6
SCNT9 6,177,436,900 91% 80% 33 31,176,729 3/3 3
SCNT10 5,527,450,200 90% 76% 34 31,140,431 5/5 0
SCNT11 5,127,529,500 89% 71% 33 31,093,228 2/2 2
miPS1 5,118,424,100 90% 76% 31 31,067,998 5/5 5
miPS2 5,463,084,500 91% 79% 30 31,098,810 3/3 3
miPS3 4,959,169,500 90% 75% 30 31,048,768 8/8 8
miPS4 4,730,980,100 90% 75% 32 31,048,646 11/11 11
2A4F1 5,450,265,400 90% 75% 30 30,823,695 10/10 10
2A4F33 5,277,562,300 89% 73% 31 30,805,337 18/19 18
1E12 4,291,623,180 84% 60% 30 30,766,265 11/11 11
2eiPS2 3,850,799,960 80% 50% 31 30,721,856 12/13 12
Quality-filtered sequence represents the amount of sequence data generated that passed the Illumina quality filter with a sequencing depth of at least 8 and
a consensus quality score of at least 30 (bp). The dbSNP percentage is the percentage of identified variants that are in the Single Nucleotide Polymorphism
Database. The shared coding region is the portion of the genome that was sequenced at high depth and quality in both the pluripotent stem cell line and
matched fibroblast (as shown in Figure 1). The projected number of somatic-coding mutations is calculated by the fraction of consensus coding sequence
identified in both pluripotent stem cells and fibroblasts.
aValidated unique mutations after removing shared mutations.
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mutations observed with the number of days in culture,
iPSCs give rise to at least twice the number of mutations
per day compared to SCNT ESCs. Although it has been
reported that reprogramming associated somatic-coding
mutations individually does not provide a selective advan-
tage to facilitate the acquisition of pluripotency during
reprogramming, it remains to be determined whether a
combination of mutations could have a role in reprogram-
ming (Ruiz et al., 2013). However, we could not rule out the
possibility that, during an extended period of induced
pluripotency, somatic mutations might selectively accu-
mulate and/or enrich over time.
Our data suggest that, when compared to induced plurip-
otency, SCNT might be a safer way to reprogram somatic402 Stem Cell Reports j Vol. 2 j 399–405 j April 8, 2014 j ª2014 The Authorcells into a pluripotent state with a lower mutation
load. Therefore, it is important to optimize the condition
of induced pluripotency into a more physiologically rele-
vant context to minimize genetic aberrations and improve
the feasibility for clinical application.EXPERIMENTAL PROCEDURES
Mice and Cell Culture
Allmouseworkwas approved by the Institutional Animal Care and
Use Committee of Peking University and UCSD. B6D2F1 mice
(8–10 weeks old) were superovulated with 7 U of pregnant mare’s
serum gonadotropin and 9 U of human chorionic gonadotropin
(HCG) 48 hr later. Metaphase II (MII) oocytes were then collected
14 hr after HCG injection for nuclear transplantation experiments.s
Table 2. Summary of Somatic Mutations Validated in Mouse
SCNT-ESC and iPSC Lines
Cell Line Mutated Genes
SCNT1 Tchhl1, Neil1, Spag9, Irf9, Opcm1, Ubr3, Lrrtm4, Susd1,
and Speg
SCNT2 n/a
SCNT3 Spata7, Col24a1, and Aff3
SCNT4 Spata7, Col24a1, and Aff3
SCNT5 Mast1 and Ccy2a4
SCNT6 Olfr963, Vmn1r197, Nckipsd, Olfr330, and Klhl22
SCNT7 Tanc1
SCNT8 Bbs1, Cyp2c39, Ndufaf3, Chd6, Cacnali, and Aldh8a1
SCNT9 Fat1, Efhd1, and Olfr118
SCNT10 Olfr963, Vmn1r197, Nckipsd, Olfr330, and Klhl22
SCNT11 Kdm3b and Il17rb
miPS1 Srsf11, Odam, Greb1, Card6, and 4930443G12Rik
miPS2 Siglec5, Tenc1, and Dusp10
miPS3 Adam5, Muc5b, Crbn, Disp2, Mtmr10, Moap1, Entpd8, and
Cntn5
miPS4 Eif3b, Acox2, Olfr1349, Ensa, Ankrd13b, Inad1, Slc39a6,
March1, 4933422H20Rik, 1700011F14Rik, and Slc12a2
2A4F1 Irx1, Gjb6, Akap6, Atp6v1e2, Abcg2, Atp9b,
2810021J22Rik, Scaf1a, and Brsk1
2A4F33 Gm16432, Zfp777, Pdzrn3, Bc016423, Rabgap11,
D16Ertd472e, Smarcc2, Arhgap17, Catsperg2, Akr7a5,
Prune2, Dip2a, Tt1, Opn5, P1xna1, Prcp, Olfr1382,
and Zfp316
1E12 Klk8, Serpinb9b, Pick1, Vps33ba, Myo5b, Grm1, Hivep1,
Ank3, Adamts12, and Cebpe
2eiPS2 Paqr6, Pold1, BC030867, Adss, Tcf4, Oas1g, M112, Ube4a,
Zfp827, Hmgc1, Dnahc2, and Tex 19.2
n/a, not applicable.
aTwo unique somatic-coding mutations were detected in this gene.
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collected from B6 mice. Primary MEFs were cultured in Dulbecco’s
modified Eagle’s media (DMEMs) supplemented with 10% fetal
bovine serum (FBS).
Nuclear Transfer
The spindle-chromosome complexes (SCCs) of MII oocytes were
enucleated using a blunt Piezo-driven pipette in a droplet of
HEPES-CZBmedium containing 5 mg/ml cytochalasin B (CB). After
enucleating, oocytes were maintained in CZB medium until injec-
tion. The fibroblast nucleus was separated and injected into the
enucleated oocytes using a Piezo drill micromanipulator. The re-Stemconstructed oocytes were cultured in CZB medium for approxi-
mately 1–3 hr before activation. Then activation was achieved
for 6 hr in calcium-free CZB medium containing 10 mM of stron-
tium chloride and 5 mg/ml of CB supplemented with 250 nM scrip-
taid. Following activation, the reconstructed embryos were
cultured in G1 with scriptaid at the same concentrations for the
next 4 hr, then subsequently cultured in G1 and G2 medium
(Vitrolife) at 37C under 5% CO2 for 3.5 days.
Establishment of SCNT-ESC Lines
The SCNT-ESC lines were established as we previously described
(Bai et al., 2007; Jiang et al., 2008; Yu et al., 2005), using knockout
DMEM (Gibco) medium supplemented with 15% FBS, 1 mM
PD0325901, and 3 mM CHIR99021, and 1,000 U/ml leukemia
inhibitory factor (LIF; Chemicon).
In Vitro Differentiation
SCNT ESCs were dissociated into single cells with 0.25% Trypsin/
EDTA (Gibco). After MEF feeder cells were depleted by incubating
cell suspension for 10 min at 37C, SCNT ESCs were transferred
onto a low-adherence plate containing the differentiationmedium
that includes Iscove’s modified Eagle medium, 15% FBS, 2 mM
GlutaMAX (Invitrogen), 1% nonessential amino acids (Invitro-
gen), 0.1 mM 2-mercaptoethanol (Invitrogen), and 1% penicillin-
streptomycin (Invitrogen). After embryoid bodies were cultured
in suspension for 4 days with a daily medium change, they were
transferred onto a 24-well plate coated with 0.1% gelatin for an
additional 5 days of spontaneous differentiation.
Immunohistochemistry
Differentiated cells were washed with PBS, fixed in 4% paraformal-
dehyde at room temperature for 20 min, and washed and blocked
with PBS containing 0.1% Triton X-100 (Sigma-Aldrich) and 10%
normal donkey serum (Jackson ImmunoResearch) at room temper-
ature for 1 hr. Samples were incubated with primary antibodies at
4C overnight, washed with PBS, and incubated with Alexa 488-
conjugated and/or Alexa 549-conjugated secondary antibodies
(Jackson ImmunoResearch) for 1 hr, then rinsed in PBS and coun-
terstained with 1 mg/ml DAPI (Roche). The following primary anti-
bodies and dilutions were used: b III-TUBULIN (1:100; Santa Cruz
Biotechnology); NEUROD2 (1:200; Santa Cruz); a-SMA (1:200;
Millipore); VIMENTIN (1:1:100; Santa Cruz); SOX17 (1:200; Milli-
pore); and AFP (1:200; Abcam). Images were visualized by laser-
scanning confocal microscopy (PerkinElmer; UltraView VoX).
Chimera Construction
Host eight-cell embryos were collected from imprinting control
region (ICR) female mice at 2.5 dpc, and seven to ten SCNT ESCs
were injected into them by a XYClone Laser System (Hamilton
Thorne Biosciences). Chimeric mice were identified by coat color,
and the male chimera was assessed for germline transmission by
mating with ICR female mice.
iPSC Generation and Characterization
Mouse iPSCs were generated as previously described by Zhao et al.
(2011). Briefly, MEFs were transfected with pCOSLNP vector usingCell Reports j Vol. 2 j 399–405 j April 8, 2014 j ª2014 The Authors 403
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(Lonza) followed by puromycin selection for 3 days and then
were plated on irradiated B6MEF feeders, cultured inmESmedium,
and treated with 5 mM PS48, 0.25 mM NaB (Stemgent), 0.5 mM
A-83-01 (Stemgent), and 0.5 mM PD0325901 (Stemgent) for
4 weeks. After iPSC colonies were picked, the cell lines were estab-
lished and expanded at roughly 3–4 days per passage, and the lack
of random integration of the episomal vector was confirmed by
Southern blotting analysis with a combinationof probes that cover
the entire episomal vector.
Whole-Genome Library Construction
Genomic DNAwas collected and then extracted using the DNeasy
Blood & Tissue Kit (QIAGEN). Next, the DNA (3 mg in 50 ml
volumes) was fragmented with Covaris AFA and then processed
following the manufacturer’s protocol (NEBNext DNA Library
Prep Master Mix Set for Illumina). Briefly, fragmented DNA was
end polished, A tailed, and then ligated to adaptors compatible
with Illumina sequencing primers. The purified and ligated prod-
ucts were amplified by PCR to generate whole-genome libraries.
Quantitative Real-Time PCR
Total RNAwas extracted and reverse transcribed into cDNA accord-
ing to the manufacturer’s protocols. Briefly, total RNA from
fibroblasts, ESCs, iPSCs, or SCNT ESCs was purified using the
QIAshredder and RNeasy Mini Kit (QIAGEN) and then reserved
transcribed into cDNA using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Quantitative PCR was
performed using the SYBR Green PCR Master Mix (Applied Bio-
systems) and previously described primers for Oct3/4 (endogenous
specific), Sox2 (endogenous specific), andNanog (Zhao et al., 2011).
UsingMicrosoft Excel, the values were averaged and normalized to
GAPDH, then calculated relative to wild-type MEFs.
Flow Cytometric Analysis
Live cells from iPSCs, SCNT ESCs, or B6 ESCs were collected,
washed with PBS, and incubated with fluorescein isothiocyanate
(FITC)-conjugated secondary antibody such as SSEA-1-FITC
(Stemgent) or IgM-FITC isotype control (BD Biosciences) prior to
fluorescence-activated cell sorting analysis.
Teratoma Assay and Histology
Teratomaswere formedby injecting one to threemillion iPSCs into
severe combined immunodeficientmice as previously described by
Zhao et al. (2011). The tumors were fixed in formalin or paraffin
embedded, sectioned, hematoxylin and eosin stained, and imaged
using an Olympus MVX10 MacroView Microscope for histology
analysis.
In-Solution Hybridization Capture with DNA Baits
In-solution hybrid capture was performed according to the manu-
facturer’s protocol (Agilent SureSelect XT Mouse All Exon Kit),
which the mouse whole-genome libraries were prepared for in-
solution hybrid capture with SureSelect mouse exon RNA for 24–
72 hr. The exome regions were recovered with streptavidin beads
after incubation, then PCR amplified with 25 ml of template,404 Stem Cell Reports j Vol. 2 j 399–405 j April 8, 2014 j ª2014 The Author2 mM each of the primers Syb_FP5 and Syb_RP7, and 50 ml Phusion
High-Fidelity Master Mix (New England Biolabs) at 98C for 30 s,
and 13 cycles of 98C for 10 s, 60C for 30 s, 72C for 30 s, and
72C for 5 min. The amplicons were purified with QIAGEN
QIAquick columns, and the libraries were sequenced on an Illu-
mina Genome Analyzer IIx or HiSeq.
Consensus Sequence Generation and Variant Calling
Variant callingwas performed as previously described byGore et al.
(2011). Briefly, sequencing reads obtained from the Illumina
Genome Analyzer or HiSeq were postprocessed and quality filtered
using GERALD. The filtered reads were mapped to the mouse
reference genome using BWA and down sampled using Picard.
The consensus sequences generated by GATK in mouse iPSC or
SCNT-ESC samples were then used to compare with progenitor
samples to find candidate novel mutations. Each heterozygous
SNP identified in iPSC or SCNT-ESC lines that was not observed
in the progenitor line was considered candidate mutations.
Sanger Validation of Candidate Mutations
Genomic DNA (6 ng) extracted from mouse iPSC, SCNT ESC, and
its somatic progenitor lines was amplified in 50 ml PCRs with
100 nM of specifically designed forward and reverse primers
around the mutation site (primers available upon request), and
25 ml of Taq 23master mix (NEB) at 94C for 2min, then 35 cycles
of 94C for 30 s, 57C for 30 s, 72C for 30 s, and final extension at
72C for 3 min. Then the PCR product was purified with QIAquick
columns. For Sanger sequencing validation, 10 ng of purified DNA
was premixed with 25 pmol of the forward primer and submitted
to Genewiz.
Statistical Analysis
The Mann-Whitney U test (unpaired, nonparametric) was per-
formed to determine whether the mouse SCNT-ESC and iPSC lines
have a significant amount of somatic-codingmutations. The result
suggests that there is a statistically significant difference between
the somatic-coding mutational load of the iPSC and SCNT-ESC
lines (p < 0.004). We used DAVID (Dennis et al., 2003) to analyze
the somatic-coding mutations identified in both iPSC and SCNT-
ESC lines and check for commonly mutated pathways. The muta-
tions do not seem to be mutated in any common pathways.
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